Late-stage clinical trials of the first two coronavirus vaccine candidates in the U.S. plan to recruit 60,000 Americans
A preexisting drug could buy time for snakebite treatment
Originally published in February 1955
Teams are starting to test vaccines using messenger RNA or chimpanzee cold viruses to inoculate humans. Will their benefits last?
The decline seen in some studies is normal, experts say. But scientists must wait to see whether infection confers long-term protection
Racial minorities and those with underlying health conditions may be at a greater risk from coronavirus infection, but have historically been less likely to be included in clinical trials...
The assay looks for stomach, esophageal, colorectal, lung and liver malignancies
Drug manufacturers are racing to create a protective measure against coronavirus without destroying the patient’s immune system
Remote clinical trials and other changes could permanently alter pharmaceutical development
Participation rates were already low, but the pandemic threatens to drive them even lower
Rates of childhood immunization have fallen across the U.S., raising the risk of vaccine-preventable disease outbreaks
With little data on what works and what doesn’t, doctors trade tips and argue about risks
The results of a trial that found dexamethasone reduced the risk of death in extremely ill coronavirus patients have yet to be published, but some doctors are already embracing them
Philip W. Askenase explains why naturally occurring exosomes are better for drug discovery.
In exosomes, our bodies have an efficient means of transmitting RNA information. Researchers want to use it to deliver drugs.
Vesicles secreted by stem cells might give clinicians a safer and simpler alternative to cell therapy, but researchers are still grappling with how best to prepare and study these tiny particles...
What scientists know about the inner workings of the pathogen that has infected the world
Unlike vials, flexible films could preserve medicines for long periods, with no refrigeration needed
Some experts caution we should temper our expectations about the much-touted approach
Biotechs and pharma want to protect patients without triggering immune system havoc